protein c: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
protein c: clinical details
Prescribing considerations
- Initiate under an experienced coagulation specialist where protein C activity can be measured.
- Acute thrombosis can substantially reduce recovery and half-life, making laboratory-guided individualisation important.
- Record the product name and batch number for biological traceability.
- Consider hepatitis A and B vaccination for people receiving repeated plasma-derived protein C products.
- Monitor more closely in renal or hepatic impairment because clinical experience is lacking.
Contraindications and cautions
- Hypersensitivity to human protein C, an excipient, mouse protein or heparin, except where treatment is required to control life-threatening thrombotic complications.
- Use particular caution with previous or suspected heparin-induced thrombocytopenia because the product may contain trace heparin.
Monitoring
- Protein C activity before and during treatment
- Clinical response and evidence of recurrent thrombosis or bleeding
- INR when transitioning to or combining treatment with a vitamin K antagonist
- Platelet count immediately if heparin-induced thrombocytopenia is suspected
- Development of inhibitory protein C antibodies if the clinical or laboratory response becomes inadequate
Clinical pharmacology
Plasma-derived, vitamin K-dependent protein C is activated by the thrombin–thrombomodulin complex. Activated protein C, aided by protein S, inactivates factors Va and VIIIa, reduces thrombin generation and has profibrinolytic activity. Intravenous administration produces an immediate but temporary increase in plasma protein C activity.
Formulation and product differences
- The selected product is a plasma-derived powder supplied with sterile water for intravenous injection.
- It contains human albumin, trisodium citrate and sodium chloride and may contain trace mouse protein or heparin.
- The reconstituted product should be used immediately and must not be mixed with other medicines.
protein c preparations and strengths
Injection
Route: Parenteral
Strengths: 500 units, 1000 units
protein c interactions
No general medicine interactions are known, but anticoagulant treatment requires particular care.
Vitamin K antagonists, including warfarin
Starting treatment can temporarily lower protein C faster than procoagulant factors, increasing the risk of thrombosis and coumarin-induced skin necrosis until anticoagulation is stable.
Other anticoagulants, including heparin
Concurrent treatment may increase bleeding risk and requires appropriate clinical and laboratory monitoring.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.